Sustaining Long-Term Adherence to PCSK9 Therapy in ASCVD

The panelists discuss strategies to improve long-term adherence to PCSK9-targeting therapies among patients with ASCVD. They note that while these agents are highly effective, adherence often declines after the first year due to cost, complex refill processes, and perceived lack of symptoms once LDL-C levels normalize. The experts emphasize that successful long-term use depends on simplifying care pathways, such as incorporating pharmacy-led coordination, automated refill reminders, and structured follow-up visits. They highlight the advantage of siRNA-based therapies like inclisiran, which require administration only twice per year, reducing the burden of self-injection and improving persistence. The panelists also stress the importance of patient education—helping individuals understand that LDL-C reduction is a lifelong goal, not a short-term fix. By combining streamlined delivery models, consistent communication, and shared accountability among the care team, clinicians can sustain adherence and maximize the benefits of PCSK9 therapy in ASCVD management.